Besides developing de novo drugs acting on the pathways that are known to be dysregulated or implicated in the phenotype of leukemia cells with MLL-rearrangements, we can also get inspired and redirect drugs already targeting those pathways in other conditions towards leukemia treatment. This evidence concerns the gene KMT2A and leukemia.